JamesKendelSchwarzMD

Oncology • Omaha, NE

Assistant Professor, Internal Medicine, University of Nebraska Medical Center College of Medicine

Join to view full profile

Are you Dr. Schwarz?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Connect with colleagues in the same hospital or clinic
You already have 74 invites waiting!
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Office
988102 Nebraska Medical Ctr
Omaha, NE 68198
Phone+1 402-559-4015
Is this information wrong?

Summary

Dr. James Schwarz, MD is an oncologist in Omaha, Nebraska. He is currently licensed to practice medicine in Nebraska, New York, and Missouri. He is affiliated with Nebraska Medicine - Nebraska Medical Center, Nebraska Medicine - Bellevue, and Memorial Community Hospital and Health System.

Education & Training

University of Missouri-ColumbiaFellowship, Hematology and Medical Oncology, 1998 - 2001
Duke University HospitalFellowship, Infectious Disease, 1990 - 1994
Duke University HospitalResidency, Internal Medicine, 1987 - 1990
Duke University School of MedicineClass of 1987

Certifications & Licensure

NE State Medical License 2008 - 2024
MO State Medical License 1998 - 2021
NY State Medical License 2001 - 2008
NC State Medical License 1989 - 1995
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer Start of enrollment: 2015 Jul 13
Completed
Phase 3

Publications & Presentations

PubMed

23 citations
Phase Ib/II clinical trial of pembrolizumab with bevacizumab for metastatic renal cell carcinoma: BTCRC-GU14-003
Arkadiusz Z. Dudek, Li C Liu, Shilpa Gupta, Theodore F. Logan, Eric A. Singer, Monika Joshi, Yousef Zakharia, Joshua M. Lang, James K. Schwarz, Anas Al-Janadi, Ajjai Alva> ;Journal of Clinical Oncology. 2020 Feb 25
48 citations
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): ove...
Daniel P. Petrylak, Ronald de Wit, Kim N. Chi, Alexandra Drakaki, Cora N. Sternberg, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aude Flechon, Aristotelis ...> ;The Lancet. Oncology. 2020 Jan 1
15 citations
Phase I/II Trial of Neoadjuvant Oregovomab-based Chemoimmunotherapy Followed by Stereotactic Body Radiotherapy and Nelfinavir For Locally Advanced Pancreatic Adenocarc...
Chi Lin, Vivek Verma, Audrey J. Lazenby, Quan P. Ly, Lyudmyla Berim, James K. Schwarz, Madi Madiyalakan, Christopher F. Nicodemus, Michael A. Hollingsworth, Jane L. Me...> ;American Journal of Clinical Oncology. 2019 Oct 1
37 citations
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan Basch, Mark C. Scholz, Johann S. de Bono, Nicholas J. Vogelzang, Paul de Souza, Gavin Marx, Ulka N. Vaishampayan, Saby George, James K. Schwarz, Emmanuel S. Anto...> ;European Urology. 2019 Jun 1
21 citations
Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma
Chi Lin, Vivek Verma, Quan P. Ly, Audrey J. Lazenby, Aaron R. Sasson, James K. Schwarz, Jane L. Meza, Chandrakanth Are, Sicong Li, Shuo Wang, Stephen M. Hahn, Jean L. ...> ;Radiotherapy and Oncology. 2019 Mar 1
2 citations
A phase 1 clinical trial of sequential pralatrexate followed by a 48-hour infusion of 5-fluorouracil given every other week in adult patients with solid tumors
Jean L. Grem, Mary E. Kos, Ruby E. Evande, Jane L. Meza, James K. Schwarz> ;Cancer. 2015 Nov 1
11 citations
Sorafenib in Relapsed AML With FMS-Like Receptor Tyrosine Kinase-3 Internal Tandem Duplication Mutation.
Smith Giri, Shadi Hamdeh, Vijaya Raj Bhatt, James K. Schwarz> ;Journal of the National Comprehensive Cancer Network. 2015 May 1
16 citations
Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer.
J. Wang, T. R. McGuire, H. C. Britton, J. K. Schwarz, F. R. Loberiza, J. L. Meza, James E. Talmadge> ;Clinical & Experimental Metastasis. 2015 Jan 25
3 citations
Safety and efficacy of preoperative sorafenib therapy in facilitating cytoreductive surgery in renal cell carcinoma.
Vijaya Raj Bhatt, Apar Kishor Ganti, James K. Schwarz, Jue Wang> ;Future Oncology. 2014 May 5
Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
Wang J, McGuire TR, Schwarz JK, Meza JL, E Talmadge JE> ;J. Clin. Oncol.. 2012-02-10
4 citations
Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: A phase II study
Nithya Ramnath, Jihnhee Yu, Nikhil I. Khushalani, Ronald Gottlieb, James K. Schwarz, Renuka Iyer, Youcef M. Rustum, Patrick J. Creaven> ;Anti-Cancer Drugs. 2008 Aug 1
67 citations
Phase II study of ispinesib in recurrent or metastatic squamous cell carcinoma of the head and neck.
Patricia A. Tang, Lillian L. Siu, Eric Chen, Sebastien J. Hotte, Stephen Chia, James K. Schwarz, Gregory R. Pond, Caitlin Johnson, A. Dimitrios Colevas, Timothy W. Syn...> ;Investigational New Drugs. 2008 Jun 1
5 citations
Phase I and Pharmacokinetic Study of Weekly Docetaxel, Cisplatin, and Daily Capecitabine in Patients with Advanced Solid Tumors
Patrick J. Creaven, Nithya Ramnath, Donald L. Trump, Milind Javle, Sandra Strychor, Trisha V. W. Repinski, Beth A. Zamboni, James K. Schwarz, Renee A. French, William ...> ;Clinical Cancer Research. 2005 Aug 15
10 citations
Advanced soft palate cancer: the clinical importance of the parapharyngeal space.
Wade G. Douglas, Nestor R. Rigual, William Giese, Joseph E. Bauer, Sam M. Wiseman, Thom R. Loree, James K. Schwarz, Sadir Alrawi, Wesley L. Hicks> ;Otolaryngology--Head and Neck Surgery. 2005 Jul 1
A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.
Reddy NM, Zamboni WC, Creaven PJ, Ramnath N, Javle MM, Strychor S, Repinski TVW, Zamboni BA, Schwarz JK, French RA, Fakih MG> ;J. Clin. Oncol.. 2005-06-01
12 citations
Pleural mesothelioma with cutaneous extension to chest wall scars
Sherry Shieh, Marcelle A. Grassi, James K. Schwarz, Richard T. Cheney> ;Journal of Cutaneous Pathology. 2004 Aug 1
A phase I and pharmacokinetic (PK) study of weekly docetaxel (D), cisplatin (P), and daily capecitabine (C) (DPC) in patients with advanced solid tumors.
Fakih MG, Zamboni WC, Ramnath N, Javle MM, Schwarz JK, French RA, Regal LL, Gorenflo RK, Creaven PJ> ;J. Clin. Oncol.. 2004-07-15
4 citations
Organ preservation in patients with squamous cancers of the head and neck.
James K. Schwarz, William Giese> ;Surgical Oncology Clinics of North America. 2004 Jan 1
227 citations
Use of the green fluorescent protein as a marker in transfected Leishmania.
D. Sean Ha, James K. Schwarz, Salvatore J. Turco, Stephen M. Beverley> ;Molecular and Biochemical Parasitology. 1996 Apr 1
355 citations
E2F1 overexpression in quiescent fibroblasts leads to induction of cellular DNA synthesis and apoptosis.
Timothy F. Kowalik, James DeGregori, James K. Schwarz, Joseph R. Nevins> ;Journal of Virology. 1995 Apr 1
Join now to see all

Hospital Affiliations

Nebraska Medicine - BellevueBellevue, Nebraska
Veterans Affairs Nebraska-Western Iowa Health Care System - LincolnLincoln, Nebraska
Nebraska Medicine - Nebraska Medical CenterOmaha, Nebraska
Memorial Community Hospital and Health SystemBlair, Nebraska